Core Insights - CDT Equity Inc. has completed initial signature mapping of its asset portfolio against Sarborg Limited's rare disease database, identifying multiple high-potential opportunities across various rare and underserved indications [1][2] Group 1: Asset Evaluation - The analysis utilized Sarborg's AI Signature Agent platform to evaluate CDT's portfolio, including its solid-form patent portfolio and licensed AstraZeneca compounds AZD1656 and AZD5658, against approximately 1,700 rare disease signatures [2] - The evaluation resulted in several statistically significant matches across therapeutic areas such as immunology, oncology, infectious disease, pediatric, and ophthalmology, indicating potential applications in orphan diseases [2] Group 2: Regulatory and Commercial Incentives - The findings are significant due to increasing regulatory and commercial incentives for rare disease development, which may include expedited regulatory pathways, smaller clinical trial designs, and enhanced market exclusivity, potentially reducing development timelines and capital requirements [3] Group 3: Strategic Advancement - CDT plans to advance these opportunities through focused, small-scale preclinical validation studies, including targeted in vivo work, to support the underlying signature data [4] - The resulting datasets are expected to form comprehensive packages for early-stage out-licensing discussions with potential partners [4] Group 4: Company Strategy - CDT's strategy focuses on identifying high-value opportunities through rapid, data-driven analysis and partnering these assets early with pharmaceutical companies or specialist investors [5] - The combination of Sarborg's signature intelligence platform and CDT's growing intellectual property portfolio offers a differentiated approach to identifying and monetizing therapeutic opportunities, particularly in high unmet medical need areas [5] Group 5: Market Potential - Certain identified opportunities are within oncology settings with limited or no currently marketed therapies, reinforcing the potential to address underserved patient populations while creating attractive partnership propositions [6]

Core Viewpoint - ParaZero Technologies Ltd. has announced a definitive agreement for a registered direct offering, raising approximately $4 million through the sale of ordinary shares and pre-funded warrants at a price of $0.75 per share [1][3]. Group 1: Offering Details - The offering includes the sale of 5,333,333 ordinary shares or pre-funded warrants at a public offering price of $0.75 per ordinary share [2]. - The pre-funded warrants are immediately exercisable and can be exercised at any time until fully exercised, with a one-for-one decrease in the number of ordinary shares for each pre-funded warrant sold [2]. - The transaction is expected to close on or about March 24, 2026, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Company Overview - ParaZero Technologies Ltd. is an aerospace defense company specializing in smart, autonomous solutions for the global manned and unmanned aerial systems industry [7]. - The company was founded in 2014 and is recognized for its advanced drone technologies, supporting various commercial, industrial, and governmental operations worldwide [7]. - ParaZero's product portfolio includes SafeAir, DefendAir, and DropAir, focusing on enhancing safety, scalability, and security in aerial operations [7].

Core Insights - XTEND has successfully completed a critical operational milestone with the U.S. Government, demonstrating its systems' performance in combat-relevant testing environments and confirming compliance with government operational requirements [1][3][4] Group 1: Contract and Delivery - The completion of an $8.8 million contract with the U.S. Government highlights XTEND's readiness to scale its systems for future operational deployment [3] - The contract included the delivery of multiple prototype operational systems, ground control equipment, and mission payload modules, along with New Equipment Training (NET) for Special Operations Forces operators [3] Group 2: Technology and Performance - XTEND's systems performed consistently during government inspections and operational performance validation, generating actionable insights for future development [4] - The technology enables seamless human-machine collaboration, enhancing the effectiveness and decision advantage of frontline forces [4] Group 3: Business Combination - JFB Construction Holdings and XTEND have entered into a definitive agreement for a business combination, which will result in the joint company being renamed XTEND AI Robotics and listed under the ticker "XTND" [6]

Core Insights - Tarsus Pharmaceuticals has achieved a $15 million milestone payment following the regulatory approval of TP-03 (lotilaner ophthalmic solution) 0.25%, marketed as XDEMVY® in the U.S., by the National Medical Products Administration (NMPA) of China [1][3] - The approval was secured by Grand Pharmaceutical Group Limited, Tarsus' exclusive partner for the development and commercialization of TP-03 in Greater China, which includes China, Hong Kong, Macau, and Taiwan [2] - TP-03 is the first and only therapy approved to address the root cause of Demodex blepharitis, benefiting over 40 million people in the region [3] Company Overview - Tarsus Pharmaceuticals focuses on advancing treatments in eye care, dermatology, and infectious disease prevention, with XDEMVY being FDA approved for Demodex blepharitis [4] - The company is also developing TP-04 for ocular rosacea and TP-05 as an oral tablet for Lyme disease prevention, both currently in Phase 2 trials [4] Financial and Partnership Details - Under the agreement with Grand Pharma, Tarsus is eligible for the $15 million milestone payment based on regulatory approval and patent issuance for TP-03, with further payments contingent on additional regulatory milestones and sales thresholds in China [3]

The evolved dual-screen laptop continues to innovate with more power, more portability, refined design, and upgraded user experienceKEY POINTS Built to last, designed to move: Tough and light Ceraluminum™ build with new hideaway hinge and new keyboard docking for travel-ready durabilityGo further, faster: 99Wh dual battery and up to Intel® Core™ Ultra X9 Series 3 processor deliver extended runtime and enhanced performanceA new reality — beyond the screens: Dual 14" 3K 1000-nit ASUS Lumina Pro OLED 144Hz dis ...

Core Insights - Off The Hook YS Inc. is launching NextBoat AI, an AI-driven platform aimed at enhancing the boat buying and selling process, at the Palm Beach International Boat Show from March 25–29, 2026 [1][5] Company Overview - Off The Hook YS Inc. is a vertically integrated, AI-powered marine marketplace and the largest buyer and seller of used boats in the U.S. [1][9] - The company was founded in 2012 and is headquartered in Wilmington, North Carolina, focusing on transforming how boats are bought, sold, and financed across the United States [8][9] Product Launch - NextBoat AI was developed as an internal tool and has been refined over two years, utilizing extensive proprietary market data to assist consumers in finding their ideal boats more efficiently [2][4] - The platform addresses inefficiencies in the marine industry, such as fragmented inventory discovery and prolonged transaction cycles [3] Technology and Functionality - Consumers can input details about their current vessel and desired purchase, and NextBoat AI will analyze proprietary data to generate real-time matches tailored to user preferences [4] - The platform continuously refines its matches as new opportunities arise, enhancing the buying experience [4] Industry Impact - The introduction of NextBoat AI is expected to enhance liquidity in the marine marketplace by aligning buyer intent with both visible and non-visible supply, thus connecting buyers and sellers more effectively than traditional brokerage models [4] Event Details - Attendees at the Palm Beach International Boat Show can experience NextBoat AI through interactive displays and demonstrations [5][6] - A giveaway of a brand-new Sea-Doo Spark 2-Seater will be held for visitors who engage with the platform at the show [7]

Core Viewpoint - Powell Max Limited has signed a non-binding Letter of Intent to acquire The Boston Solar Company for a transaction valued at $9.0 million, which includes the assumption of up to $7.0 million in debt [1][2]. Company Overview - Powell Max Limited is a financial communications services provider headquartered in Hong Kong, with a U.S. subsidiary in Delaware and corporate staff in Boca Raton, Florida. The company offers a range of financial communications services to support capital market compliance and transaction needs for corporate clients [9]. - Boston Solar is a vertically-integrated regional EPC solar installer focused on Massachusetts and the broader New England area, providing a complete solar system solution from financing to design and installation [3]. Financial Performance - Boston Solar reported a 22% increase in revenue for 2025, reaching $24 million, with an adjusted net income of $2 million based on unaudited management accounts [4]. Strategic Intent - The acquisition of Boston Solar is part of Powell Max's growth strategy, aiming to capitalize on rising energy demand in the U.S. and to diversify and expand its operations [5]. - Following the acquisition, Powell Max plans to provide Boston Solar with up to $20 million in working capital to support geographic expansion and pursue additional acquisitions in the solar installation industry [2][5]. Management and Leadership - Boston Solar is led by President Mike Morlino, a distinguished U.S. Navy SEAL veteran, who has a background in operational improvement projects [7]. - Powell Max intends to retain the current senior management team of Boston Solar after the acquisition [6].

Company Overview - Rubico Inc. is a global provider of shipping transportation services specializing in the ownership of vessels [2] - The company operates two modern, fuel-efficient, eco-friendly Suezmax tankers with a deadweight tonnage of 157,000 dwt [2] - Rubico is incorporated under the laws of the Republic of the Marshall Islands and has its executive offices in Athens, Greece [2] - The company's common shares are traded on the Nasdaq Capital Market under the symbol "RUBI" [2] Recent Developments - Rubico Inc. has filed its annual report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission [1] - The annual report can be accessed through the company's website or the SEC's website [1]

Core Viewpoint - Alto Ingredients, Inc. is actively participating in the H.C. Wainwright Renewable Fuels Virtual Day, indicating its engagement in the renewable fuels sector and commitment to investor relations [1]. Company Overview - Alto Ingredients, Inc. (NASDAQ: ALTO) specializes in the production and distribution of renewable fuel, essential ingredients, and specialty alcohols [2]. - The company serves a diverse range of markets, including Health, Home & Beauty; Food & Beverage; Industry & Agriculture; Essential Ingredients; and Renewable Fuels [2].

VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Liberty Gold Corp. (TSX: LGD; OTCQX: LGDTF) (“Liberty Gold” or the “Company”) announces that it has entered into a definitive share purchase agreement (the “Agreement”) to sell the issued and outstanding shares of its subsidiary, Speciality American Metals Inc., that owns the Goldstrike Project located in southern Utah (“Goldstrike”), to Heliostar Metals Ltd. (“Heliostar”) for US$72.5 million in total consideration (the “Transaction”). The Tran ...